Glutathione USP,L-Glutathione reduced
Disclosures: Kathryn Schmidt: Nothing to Disclose, Jessica Grimm: Nothing to Disclose, Devin Copley: Nothing to Disclose, Daniel Penrice: Nothing to Disclose, Barbara Copeland: Nothing to Disclose, William Harmsen: Nothing to Disclose, Rachel Gullerud: Nothing to Disclose, Winnie Fan: Nothing to Disclose, Jordan Coffey: Nothing to Disclose, Julianne Lunde: Nothing to Disclose, Sarah Harper: Nothing to Disclose, Hugo Vargas: Sequana Medical: Consultant, Mallinckrodt: Consultant, Ocelot: Grant/Research Support, Arrowhead Phama: Grant/Research Support, Takeda: Grant/Research Support, Durect: Grant/Research Support, River2Renal: Grant/Research Support, Genfit: Grant/Research Support, Kezar Pharmaceuticals: Grant/Research Support, Blanca Lizaola-Mayo: Nothing to Disclose, Douglas Simonetto: Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose 1764 PREVALENCE OF COMPENSATED ADVANCED CHRONIC LIVER DISEASE (CACLD) IN THE UNITED STATES: INSIGHTS FROM NHANES 2017-2020 Ritik Mahaveer Goyal 1 Apoorva Doshi 2 Supriya Maheshwari 3 Imran Qureshi 1 Udita Gupta 3 David Kim 1 Paul Gaglio 1 , 1 Rutgers New Jersey Medical School, 2 Seth GS Medical College and KEM Hospital, Mumbai, 3 University of Alabama at Birmingham Background: Compensated Advanced Chronic Liver disease (cACLD) is described in the Baveno VI consensus which defines it as a continuum of severe fibrosis and cirrhosis as these patients are clinically inseparable
Under aseptic conditions, sterilized seeds were grown on square plates on MS media supplemented with 50, 100, 150, 200, and 300 mM NaCl (0 mM NaCl was used as a control)
doi: 10.1016/j.bbrc.2007.07.088
